Acquisition synergies Post-acquisition by Schott AG, leverage integrated single-source manufacturing capabilities to offer end-to-end microarray and biosensor production services to diagnostics labs and contract research organizations seeking streamlined supply chains.

Diagnostics demand Strong focus on disease diagnostics and SNP assays via microarrays positions AMI to target clinical laboratories, OEM diagnostic developers, and pharma partnerships needing custom arrays and rapid scanner capabilities.

Advanced tooling Recent and ongoing releases of improved microarray scanners suggest upsell opportunities for customers requiring upgraded analytics, higher throughput, and validated imaging hardware to complement arrays.

SME collaboration Small team size indicates high agility; target boutique genomics labs and contract manufacturers looking for flexible, personalized service, faster turnaround, and bespoke array designs.

Strategic partnerships Past collaborations with Novacyt and Primerdesign imply openness to co-development; pursue new partnerships with diagnostic developers and SNP assay providers to expand footprints in SNP-based diagnostics.